(TheNewswire)
LONDON, ON – TheNewswire - May 17, 2021 -- Sernova Corp . (TSXV:SVA)(FSE/XETRA:PSH)(OTC:SEOVF), aleading clinical-stage company focused on regenerative medicinetherapeutics, today announced that Dr. Philip Toleikis, President andCEO, will present at the virtual Global Partnership Family Office –Healthcare & Biotechnology TSX Showcase on May 19 th , 2021. TheShowcase is hosted by London, UK based International Deal Gateway(IDG).
The event is by invitation only and includes a selected group of inspiring leaders frominnovative public companies in the healthcare, biotechnology and lifesciences sector. Five leading companies listed on the TSX or TSXVenture have been selected to present live, via video, to GPFOinvestors .
“Deal Gateway’s exclusive virtual events giveinnovative leaders the opportunity to introduce their companies to avery hard to reach audience of family offices and access new pools ofcapital in London, Geneva, Zurich and other key markets,” saidElizabeth Priestman, CEO of IDG.
“Sernova is delighted to have been selected by theTSX to present to this exclusive group of sophisticated investors,”said Dr. Philip Toleikis, President and CEO of Sernova. “Thispresentation aligns with our goal to increase the percentage oflonger-term oriented institutional investors amongst our shareholderbase who understand the value of innovative technologies. We lookforward to presenting to them and outlining the potential ofSernova’s innovative regenerative medicine platform, includingpotentially providing a ‘functional cure” for diabetes and otherchronic diseases.”
Following the event, a recording will be available at www.sernova.com .
Selected Company Achievements
-
- Integrated regenerative medicine therapeutic platformsolution including an implantable device with local immune protection(Conformal Coating Technology) that could eliminate the need forimmunosuppressive medications to protect cells from immune systemattack.
- First and only regenerative medicine therapeuticsplatform company to demonstrate an implantable well-vascularizedsubcutaneous cell transplant device technology achieving persistentislet graft function and clinical benefit as presented in the mostadvanced study patients in its ongoing US Phase I/II diabetes clinicaltrial.
- Demonstrated preclinical proof-of-concept showingimprovement in blood clotting with human cells using an ex vivo genetherapy approach for hemophilia A
- Demonstrated preclinical proof-of-concept withtransplanted human thyroid tissue for management of hypothyroiddisease.
- Multiple research collaborations in place withpharmaceutical industry leaders.
About Global Partnership FamilyOffice (GPFO) and International Deal Gateway (IDG)
International Deal Gateway's Family Office Eventsprovide a unique opportunity for public and private companies to gainaccess to an exclusive group of 2,400 ultra-high net worth investorsand family offices throughout Europe through their long-standingrelationship with GPFO. Together, IDG and GPFO look forward to hostingthe TSX sponsored Healthcare & Biotechnology Showcase, acollection of extraordinary select companies working to improve healthoutcomes with a focus on longevity, healthcare, biotechnology anddata.
GPFO has been the 'eyes and ears' of the global familyoffice community for over a decade. Providing salient, timely andimpartial briefings, insights and opportunities to itsmembership.
Dr. Michael J. Oliver, GPFO founder, "We have beendelighted to grow our partnership with IDG over the years, providingour community with insights from the brightest minds and leaders fromacross the Atlantic, offering a bridge for many of our network whohave deep familial and business ties to Canada and theUS."
About Sernova
Sernova is developing regenerative medicine therapeutictechnologies using its Cell Pouch medical device, therapeutic cells(i.e., human donor cells, corrected human cells, stem cell-derivedcells and tissues) and immune protection technologies to improve thetreatment and quality of life of people living with chronic metabolicdiseases such as insulin-dependent diabetes, blood disorders includinghemophilia, and other diseases treated through replacement of proteinsor hormones missing or in short supply within the body. For moreinformation, please visit www.sernova.com .
CONTACTS:
Sernova Corp
Dominic Gray
Head of Communications
(519) 858-5126
Forward-Looking Information
This release may contain forward-lookingstatements. Forward-looking statements are statements that are nothistorical facts and are generally, but not always, identified by thewords "expects", "plans", "anticipates","believes", "intends", "estimates","projects", "potential" and similar expressions,or that events or conditions "will", "would","may", "could" or "should" occur.Although Sernova believes the expectations expressed in suchforward-looking statements are based on reasonable assumptions, suchstatements are not guarantees of future performance, and actualresults may differ materially from those in forward-lookingstatements. Forward-looking statements are based on the beliefs,estimates, and opinions of Sernova’s management on the date suchstatements were made, which include our beliefs about the conduct andoutcome of clinical trials and the potential of local immuneprotection technologies. Sernova expressly disclaims any intention orobligation to update or revise any forward-looking statements whetheras a result of new information, future events orotherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.